C5 and COVID-19: Strikingly, agents targeting C5–C5a–C5aR1 or glycosphingolipid-lowering therapies have been linked to the disruption of the SARS-CoV-2 replication and the suppression of the SARS-CoV-2-induced activation of immune inflammation in COVID-19 [24,78,350,351].